(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.21%) $11.02
(0.56%) $0.808
(-0.95%) $93.01
5 days till quarter result
(bmo 2024-04-24)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally...
Stats | |
---|---|
Today's Volume | 30 816.00 |
Average Volume | 23 848.00 |
Market Cap | 84.02M |
EPS | CHF0 ( 2024-03-26 ) |
Next earnings date | ( CHF0 ) 2024-04-24 |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | -1.060 |
ATR14 | CHF0.0530 (0.57%) |
Volume Correlation
Santhera Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Santhera Pharmaceuticals Correlation - Currency/Commodity
Santhera Pharmaceuticals Financials
Annual | 2022 |
Revenue: | CHF7.47M |
Gross Profit: | CHF3.88M (51.93 %) |
EPS: | CHF-11.67 |
Q2 | 2023 |
Revenue: | CHF3.94M |
Gross Profit: | CHF1.71M (43.29 %) |
EPS: | CHF-2.09 |
Q1 | 2023 |
Revenue: | CHF1.97M |
Gross Profit: | CHF1.01M (51.05 %) |
EPS: | CHF-1.050 |
Q4 | 2022 |
Revenue: | CHF1.22M |
Gross Profit: | CHF-805 000 (-65.82 %) |
EPS: | CHF-6.43 |
Financial Reports:
No articles found.
Santhera Pharmaceuticals
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators